Matthias Preusser, Professor and Head of Medical Oncology at the Medical University of Vienna, shared on LinkedIn:
“Just presented at EANO2026 in Rome and published in The Lancet: results of the ROAM/EORTC-1308 phase 3 trial.
Should patients with a completely resected WHO grade 2 atypical meningioma receive adjuvant radiotherapy or observation? ROAM/EORTC-1308 is the first randomized phase 3 trial addressing this long-standing clinical question and provides class I evidence.
We randomized 157 patients to adjuvant radiotherapy (60 Gy in 30 fractions) or observation.
Key results:
- 5-year disease-free survival: 79.9% with radiotherapy vs 64.3% with observation
- HR 0.51 (95% CI 0.27–0.97), p=0.0396
- Recurrence: 14% vs 30%
- Grade 2/3 SAEs in 5/66 (8%) participants with radiotherapy
- Molecular classification is prognostic and did not alter the primary outcome
Implication: Adjuvant radiotherapy significantly improved disease-free survival after complete resection of WHO grade 2 atypical meningioma and should be offered to patients. Importantly, treatment decisions should remain individualized, balancing the reduction in recurrence risk against the potential adverse effects of radiotherapy.
Many thanks to all patients, investigators and collaborators across the 58 centres in 11 countries who made ROAM/EORTC-1308 possible.”
Title: Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial
Authors: Michael D Jenkinson, Anna Rosala-Hallas, Felix Sahm, Nicolaus Andratschke, Keyoumars Ashkan, Damiano Balestrini, Helen Bulbeck, Sílvia Comas, Giovanna Culeddu, Kumar Das, Laura Fariselli, Karen Fowkerer, Priya Francis, Efstathia Gkioni, Vassilis Golfinopoulos, Thierry Gorlia, Neda Haghighi, Brian J Haylock, Dyfrig A Hughes, Mohsen Javadpour, Philippe Martinive, Helen M O Mayles, Perry Moore, Emilie Le Rhun, Nicola Rosenfelder, Gail Ryan, Michael Weller, Carrol Gamble, Matthias Preusser, Damien C Weber
Read the Full Article